Study identification

PURI

https://redirect.ema.europa.eu/resource/49608

EU PAS number

EUPAS44961

Study ID

49608

Official title and acronym

Hearing loss and risk of major osteoporotic fracture: a population-based cohort study in the United Kingdom (20200418)

DARWIN EU® study

No

Study countries

United Kingdom

Study description

The overarching aim is to assess the association between hearing loss/impairment and fracture risk using the Clinical Practice Research Datalink (CPRD) and to generate a new short-term (1-year) as well as long-term (10-year) major osteoporotic fracture risk prediction tool for patients with hearing loss that will help clinicians to identify a population at high-risk of fracture.

Study status

Finalised
Research institutions and networks

Institutions

Amgen
United States
First published:
21/02/2024
Institution

Contact details

Global Development Leader Amgen Inc.

Primary lead investigator
Study timelines

Date when funding contract was signed

Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Amgen
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable